Jonathan Pan,
Director,
GlaxoSmithKline Oncology
Jonathan L. Pan, PhD, heads the oncology companion diagnostic and disease strategy within GSK Oncology. In his role, he works closely with diagnostic stakeholders globally, particularly pathologists, oncologists, payors, and policy makers to ensure that diagnostic testing is not a barrier to appropriate therapeutic treatments. His focus is on both currently marketed therapeutics as well as pipeline products to ensure that the proper diagnostic infrastructure is in place in different markets. Prior to joining GSK, Jonathan helped to establish the pharmaceutical practice at Scientia Advisors, a boutique consulting firm in Boston. There, he worked on innovation, portfolio, and competitive strategies for pharmaceutical, medical device, and diagnostic companies – looking at unique synergies and opportunities to engage the market. In addition, Jonathan was a senior consultant on IMS Consulting Groups’ Product and Portfolio Strategy team as well as a consultant on Deloitte’s Consulting Enterprise Risk Strategy team, servicing federal clients such as the Nuclear Regulatory Commission, Health and Human Services, and Department of Education. Jonathan also has experience in due diligence working in the middle markets for large private equity providing leveraged buy-out options or mezzanine financing. Jonathan is a proud University of Michigan graduate earning his PhD in cellular and molecular biology and an MBA in management.
|
|
|